Curasight is a clinical phase II company with a technology built around the uPAR receptor, which is a biomarker expressed in most solid cancers. Curasight operates in the diagnosis and treatment of various cancers.
The company has developed a radiopharmaceutical platform that can be used both for diagnostics and for the treatment of cancer: uTRACE – which is used for cancer diagnostics has been used in more than 400 patients in a number of completed and ongoing investigator-initiated phase II clinical trials; and uTREAT – which have been successfully used in the treatment of cancer in translational studies.
What you see is what you treat!
Curasight is a successful Danish theranostic Phase 2 biotech company focused on diagnosing and treating cancer through Targeted Radionuclide Therapy – currently in brain cancer, prostate cancer, head and neck cancer and neuroendocrine cancer. With Curasight’s technology (uTRACE and uTREAT), cancer can be diagnosed and treated at the cellular level without harming healthy cells, so that what you can detect of cancer is what you treat with radiation: What you see is what you treat.
The main points of Curasight’s investment case are therefore a conviction that Cursasight’s targeted radiotherapy and diagnostics will initially achieve positive progress in the development/studies and thus that the company will be interesting for partnerships with e.g. Big Pharma and achieve the company’s objectives. The company has already landed a large deal for uTRACE in prostate cancer in collaboration with Curium, where Curasight will receive up to MUSD 70 in commercial and development milestones and double-digit royalties on sales.
Curasight’s objectives are:
Continued expansion of the pipeline, which will particularly strengthen the ability to enter into partnerships
Curasight’s pipeline as of Q3 2023:
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.